CDH1 and carcinoma: Given the high E-Cadherin expression in normal urothelium and the high positivity rate in invasive urothelial cancer, the comparatively high number of non-invasive papillary urothelial pTaG2 low grade carcinoma with loss of E-Cadherin immunostaining was highly unexpected.